Natalizumab-withdrawal-in-multiple-sclerosis-RR-patients-what-to-expect

Abstract

Background: Postmarketing studies have shown a considerable efficacy of natalizumab (NAT) in RRMS, while progressive multifocal leukoencephalopathy (PML) is a well-known risk associated with long-term therapy. To minimize this risk, treatment with NAT is often stopped after 2years. However, the features of clinical and radiological disease activity after NAT withdrawal are still unknown.